Eventide Asset Management’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Eventide Asset Management’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4,500	Closed	-$3.02M	–	150
2017 Q4	$3.02M	Hold	4,500	–	–	0.16%	94
2017 Q3	$2.83M	Hold	4,500	–	–	0.16%	92
2017 Q2	$2.16M	Hold	4,500	–	–	0.13%	95
2017 Q1	$3.38M	Buy	4,500 +172	+4%	+$154K	0.22%	84
2016 Q4	$4.24M	Buy	4,328 +1,739	+67%	+$1.99M	0.28%	74
2016 Q3	$3.5M	Hold	2,589	–	–	0.21%	80
2016 Q2	$2.27M	Hold	2,589	–	–	0.14%	97
2016 Q1	$3.62M	Hold	2,589	–	–	0.2%	84
2015 Q4	$4.78M	Buy	2,589 +569	+28%	+$1.14M	0.24%	89
2015 Q3	$3.95M	Buy	+2,020	New	+$4.72M	0.23%	83

Other funds holding TCON

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PCM

Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Eventide Asset Management's TCON Position: Q1 2018 in Review

Eventide Asset Management sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q1 2018, closing a stake of 4,500 shares — an estimated $3.02M sold.

Eventide Asset Management first reported a position in TCON in Q3 2015 and held it in 10 quarters. The position peaked at $4.78M in Q4 2015. 33 funds tracked by Wall St. Rank hold TCON as of Q1 2018.

Eventide Asset Management reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Eventide Asset Management sold 4,500 TRACON Pharmaceuticals, Inc. Common Stock shares in Q1 2018, an estimated $3.02M.
Eventide Asset Management first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q3 2015 and held it in 10 quarters.
Eventide Asset Management's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $4.78M in Q4 2015.
33 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q1 2018.

Based on Eventide Asset Management's 13F filing for Q1 2018, filed 15 May 2018.